Premium
Activity of 4‐HPR in superficial bladder caner using DNA flow cytometry as an intermediate endpoint
Author(s) -
Decensi Andrea,
Bruno Silvia,
Giaretti Walter,
Torrisi Rosalba,
Curotto Antonio,
Gatteschi Beatrice,
Geido Elio,
Polizzi Anna,
Costantini Massimo,
Bruzzi Paolo,
Nicolò Guido,
Costa Alberto,
Boccardo Francesco,
Giullani Luciano,
Santi Leonardo
Publication year - 1992
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.240501327
Subject(s) - flow cytometry , chemistry , dna , microbiology and biotechnology , biology , biochemistry
The ability ofthesynthetic retinoid N ‐(4‐hydroxyphenyl) retinamide (4‐HPR) to affect the outcome of previously resected superficial bladder cancer was investigated in apilot study using DNA content flow cytometry and conventional cytology as intermediate endpoints. Twelve patients were treated with oral 4‐HPR (200 mg daily) and compared with 17 non‐randomized, untreated controls. The median interval between transurethral resection and 4‐HPR administration was 5.5 months (rangs 0–36). The median follow‐up period was 12 months (rang 3–31) in the4‐HPR group and 9 months (range 2–22) in the control group. The proportion of patients with DNA aneuploid stemlines in bladder‐washed cells decreased form 7/12 (58%) to5/11 (45%) in the 4‐HPR group, but increased form 7/17 (41%) to 10/17(59%) in the control group. In patients with stable diploid profiles, mean (±SE) S‐phase and G2‐M‐phase fractions decreased in the course of retinoid treatment from basal levels of 15.2±4.1% to 7.5±3.3% and 10.3±2.2% to 5.2 ±0.4%, respectively. The same parameters in the control group changes from basal levels of 14.6±3.4% to 12.4±2.7% and 9.8±1.6% to 12.6±1.6%, respectively. Positive or suspicious cytologic examinations were present in 3/12 (25%) treated cases prior to 4‐HPR) administration and all subsequently reverted to normal. The same parameter in the control group increased from 4/17 (24%) to 6/17 (35%)during follow‐up. Impaired adaptation to darekness was recorded in 4 patients, and transient dermatologic alterations were observed in one‐third of the patients, requiring dose reduction in one case. Our preliminary data suggest that4‐HPR may affect theDNA content and abnormal cytology in patients with previously resected superficial bladder cancer. © 1992 Wiley‐Liss, Inc.